Abstract Cluster of differentiation 40 (CD40) mediates many immune activities. Preclinical
studies have shown that activation of CD40 can evoke massive antineoplastic effects in …

Agonist antibodies that target immune checkpoints, such as those in the tumor necrosis
factor receptor (TNFR) superfamily, are an important class of emerging therapeutics due to …

The PD-1 receptor triggers a negative immunoregulatory mechanism that prevents
overactivation of immune cells and subsequent inflammatory diseases. Because of its …

Immunotherapy has shown promising results in cancer treatment. Research shows that most
patients might be resistant to these therapies. So, new immune therapies are needed. OX40 …

With the exception of a few signaling incompetent decoy receptors, the receptors of the
tumor necrosis factor receptor superfamily (TNFRSF) are signaling competent and engage …

Immunotherapy has shown great potential in the treatment of cancer; however, only a
fraction of patients respond to treatment, and many experience autoimmune‐related side …

Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour
efficacy in multiple preclinical models but modest clinical responses. This might reflect …

Agonist antibodies that activate cellular signaling have emerged as promising therapeutics
for treating myriad pathologies. Unfortunately, the discovery of rare antibodies with the …

Co-stimulation signaling in various types of immune cells modulates immune responses in
physiology and disease. Tumor necrosis factor receptor superfamily (TNFRSF) members …

Tumor evasion has recently been associated with a novel member of the B7 family, HERV‐H
LTR‐associating 2 (HHLA2), which is mostly overexpressed in PDL‐1neg tumors. HHLA2 …